company background image
YCBD

cbdMD NYSEAM:YCBD Stock Report

Last Price

US$0.28

Market Cap

US$17.0m

7D

21.2%

1Y

-84.9%

Updated

06 Oct, 2022

Data

Company Financials +
YCBD fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

YCBD Stock Overview

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products.

cbdMD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for cbdMD
Historical stock prices
Current Share PriceUS$0.28
52 Week HighUS$2.14
52 Week LowUS$0.20
Beta2.01
1 Month Change-22.05%
3 Month Change-24.32%
1 Year Change-84.87%
3 Year Change-91.05%
5 Year Changen/a
Change since IPO-90.28%

Recent News & Updates

Shareholder Returns

YCBDUS PharmaceuticalsUS Market
7D21.2%-0.2%3.3%
1Y-84.9%3.6%-20.4%

Return vs Industry: YCBD underperformed the US Pharmaceuticals industry which returned 6.2% over the past year.

Return vs Market: YCBD underperformed the US Market which returned -18.8% over the past year.

Price Volatility

Is YCBD's price volatile compared to industry and market?
YCBD volatility
YCBD Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement11.3%
Market Average Movement6.9%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: YCBD is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: YCBD's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015105n/ahttps://www.cbdmd.com

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids.

cbdMD Fundamentals Summary

How do cbdMD's earnings and revenue compare to its market cap?
YCBD fundamental statistics
Market CapUS$16.96m
Earnings (TTM)-US$62.81m
Revenue (TTM)US$37.34m

0.5x

P/S Ratio

-0.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
YCBD income statement (TTM)
RevenueUS$37.34m
Cost of RevenueUS$13.35m
Gross ProfitUS$23.99m
Other ExpensesUS$86.80m
Earnings-US$62.81m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.04
Gross Margin64.25%
Net Profit Margin-168.24%
Debt/Equity Ratio0.02%

How did YCBD perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is YCBD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for YCBD?

Other financial metrics that can be useful for relative valuation.

YCBD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.3x
Enterprise Value/EBITDA-0.6x
PEG Ration/a

Price to Sales Ratio vs Peers

How does YCBD's PS Ratio compare to its peers?

YCBD PS Ratio vs Peers
The above table shows the PS ratio for YCBD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.6x
KALA Kala Pharmaceuticals
2.4x-42.1%US$19.8m
IGXT IntelGenx Technologies
11.3xn/aUS$19.4m
CLSH.D CLS Holdings USA
0.3xn/aUS$6.5m
UPC Universe Pharmaceuticals
0.3xn/aUS$13.9m
YCBD cbdMD
0.5x24.2%US$17.0m

Price-To-Sales vs Peers: YCBD is good value based on its Price-To-Sales Ratio (0.5x) compared to the peer average (3.6x).


Price to Earnings Ratio vs Industry

How does YCBD's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: YCBD is good value based on its Price-To-Sales Ratio (0.5x) compared to the US Pharmaceuticals industry average (3x)


Price to Sales Ratio vs Fair Ratio

What is YCBD's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

YCBD PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.5x
Fair PS Ratio5.7x

Price-To-Sales vs Fair Ratio: YCBD is good value based on its Price-To-Sales Ratio (0.5x) compared to the estimated Fair Price-To-Sales Ratio (5.7x).


Share Price vs Fair Value

What is the Fair Price of YCBD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate YCBD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate YCBD's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is cbdMD forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


24.2%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if YCBD's forecast earnings growth is above the savings rate (1.9%).

Earnings vs Market: Insufficient data to determine if YCBD's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if YCBD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: YCBD's revenue (24.2% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: YCBD's revenue (24.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if YCBD's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has cbdMD performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-20.0%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: YCBD is currently unprofitable.

Growing Profit Margin: YCBD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: YCBD is unprofitable, and losses have increased over the past 5 years at a rate of 20% per year.

Accelerating Growth: Unable to compare YCBD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: YCBD is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: YCBD has a negative Return on Equity (-125.49%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is cbdMD's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: YCBD's short term assets ($19.9M) exceed its short term liabilities ($5.7M).

Long Term Liabilities: YCBD's short term assets ($19.9M) exceed its long term liabilities ($4.8M).


Debt to Equity History and Analysis

Debt Level: YCBD has more cash than its total debt.

Reducing Debt: Insufficient data to determine if YCBD's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: YCBD has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: YCBD has less than a year of cash runway if free cash flow continues to reduce at historical rates of 16% each year


Discover healthy companies

Dividend

What is cbdMD current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

cbdMD Dividend Yield vs Market
How does cbdMD dividend yield compare to the market?
SegmentDividend Yield
Company (cbdMD)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.6%
Industry Average (Pharmaceuticals)2.6%
Analyst forecast in 3 Years (cbdMD)n/a

Notable Dividend: Unable to evaluate YCBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate YCBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if YCBD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if YCBD's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as YCBD has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

cbdMD has no CEO, or we have no data on them.


Leadership Team

Experienced Management: YCBD's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: YCBD's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of YCBD?
Owner TypeNumber of SharesOwnership Percentage
Institutions9,477,49815.7%
Individual Insiders19,442,82232.1%
General Public31,635,27552.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Top 25 shareholders own 46.45% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
27.84%
Raymond Coffman
16,860,746$4.7m1.62%no data
3.13%
Martin Sumichrast
1,894,553$530.5k2.23%no data
2.64%
Mirae Asset Global Investments Co., Ltd
1,599,648$447.9k24.63%no data
2.06%
Merlin Capital LLC
1,250,454$350.1k-29.1%0.59%
1.92%
The Vanguard Group, Inc.
1,165,601$326.4k-0.61%no data
1.43%
AdvisorShares Investments, LLC
867,649$242.9k-14.75%0.05%
1.08%
BlackRock, Inc.
653,390$182.9k-11.36%no data
0.95%
Columbia Management Investment Advisers, LLC
573,169$160.5k-2.57%no data
0.87%
Penserra Capital Management LLC
528,960$148.1k5.08%no data
0.54%
Geode Capital Management, LLC
328,468$92.0k-1.51%no data
0.5%
Peter Ghiloni
303,750$85.1k0%no data
0.48%
Bridgeway Capital Management, LLC
290,800$81.4k-20.5%no data
0.38%
Cambria Investment Management, L.P.
232,040$65.0k0%0.01%
0.33%
Group One Trading LP, Asset Management Arm
200,208$56.1k-11.96%no data
0.29%
John Wiesehan
176,450$49.4k0%no data
0.28%
Renaissance Technologies LLC
170,875$47.8k82.56%no data
0.23%
Davy Asset Management Limited
139,762$39.1k5.04%no data
0.21%
Vident Investment Advisory, LLC
125,700$35.2k5.38%no data
0.21%
ACT Capital Management
125,000$35.0k0%0.04%
0.21%
Davy Global Fund Management Limited
124,936$35.0k-3.07%0.01%
0.19%
Swisspartners (liechtenstein) AG
115,462$32.3k-3.78%0.03%
0.19%
swisspartners Advisors Ltd.
115,462$32.3k0%0.01%
0.19%
State Street Global Advisors, Inc.
114,303$32.0k4.67%no data
0.16%
William Raines
97,674$27.3k0%no data
0.12%
Susquehanna International Group, LLP, Asset Management Arm
74,395$20.8k27.59%no data

Company Information

cbdMD, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: cbdMD, Inc.
  • Ticker: YCBD
  • Exchange: NYSEAM
  • Founded: 2015
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$16.956m
  • Shares outstanding: 60.56m
  • Website: https://www.cbdmd.com

Number of Employees


Location

  • cbdMD, Inc.
  • 8845 Red Oak Boulevard
  • Charlotte
  • North Carolina
  • 28217
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
YCBDNYSEAM (NYSE MKT LLC)YesCommon StockUSUSDDec 2018
YCBD.PRANYSEAM (NYSE MKT LLC)8% SER A CUM PFDUSUSDOct 2019

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/10/06 00:00
End of Day Share Price2022/10/06 00:00
Earnings2022/06/30
Annual Earnings2021/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.